en 23408747 It has recently been shown that ROR1, a member of the receptor tyrosine kinase family, is overexpressed in leukemic B cells of Chronic Lymphocytic Leukemia (CLL) and a subset of Acute Lymphoblastic Leukemia (ALL). In this comparative study the expression profile of ROR1 mRNA was investigated in Iranian patients with CLL and Acute Myelogenous Leukemia (AML) and the results were compared with those previously reported in our Iranian ALL patients. RT-PCR was performed on bone marrow and/or peripheral blood samples of 84 CLL and 12 AML patients. CLL samples were classified into immunoglobulin heavy chain variable region (IGHV) gene mutated (n=55) and unmutated (n=29) and also indolent (n=42) and progressive (n=39) subtypes. ROR1 expression was identified in 94% of our CLL patients, but none of the AML patients expressed ROR1. No significant differences were observed between different CLL subtypes for ROR1 expression. Taken together the present data and our previous results on ROR1 expression in ALL, our findings propose ROR1 as a tumor-associated antigen overexpressed in a large proportion of lymphoid (CLL and ALL), but not myeloid (AML) leukemias. Expression of ROR1 seems to be associated to lineage and differentiation stages of leukemic cells with a potential implication for immunotherapy. Acute myelocytic leukemia, Chronic lymphocytic leukemia, ROR1, RT-PCR 119 125 https://www.ajmb.org/En/Article.aspx?id=65 https://www.ajmb.org/PDF/En/FullText/65.pdf MahdiShabaniDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran125HosseinAsgarian-OmranDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran238MohammadHojjat-FarsangiDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran239ParvanehVossoughClinic of Hematology, Ali-Asghar Hospital, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran240RamazanA.SharifianClinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran241Gholam RezaTougheClinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran242Seyed MohsenRazaviClinic of Hematology and Oncology, Firozgar Hospital, Faculty of Medicine, Iran University of Medical Sciences , Tehran, Iran243JalalKhoshnoodiDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran168MahmoodJeddi-TehraniMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran15HodjattallahRabbaniImmune and Gene Therapy Lab, Cancer Center Karolinska, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden24FazelShokriMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran5